WO2014042290A1

WO2014042290A1 - Novel use method for cyclic depsipeptide

Info

Publication number: WO2014042290A1
Application number: PCT/JP2013/077279
Authority: WO
Inventors: 中尾　洋一; 寛前島; 土井　隆行; 山下　潤; 英毅魚崎; 福島　弘之
Original assignee: 国立大学法人京都大学
Priority date: 2012-09-03
Filing date: 2013-10-07
Publication date: 2014-03-20
Also published as: JP2014047193A; JP6024880B2

Abstract

　A pharmaceutical composition containing at least one compound selected from the group consisting of a cyclic depsipeptide represented by formula (I) or (II), medically acceptable salts of same, solvates of same and prodrugs of same, and a manufacturing method for cardiomyocytes, said method including a step for bringing the above-mentioned compound into contact with cardiac progenitor cells. (In the formulas: R₁ and R₃ are each independently H or a C1-C6 alkyl group; R₂ is a substituent group selected from the group consisting of H, a C1-C6 alkyl group, a trimethylsilyl group and a triethylsilyl group; R₄ is a substituent group selected from the group consisting of H, OH, a C1-C6 alkoxy group, F, Cl, Br and I; L-M has a structure selected from the group consisting of CH=C(Me), CH=CH, CH₂-CH₂ and CH₂-CH(Me); X is O or S; and n is 1 or 2.)

Description

Novel usage of cyclic depsipeptide

The present invention relates to a pharmaceutical composition containing a cyclic depsipeptide and a method for efficiently differentiating and proliferating cardiomyocytes and / or myocardial progenitor cells using the cyclic depsipeptide.

Since adult cardiomyocytes have lost the ability to divide, it has been considered difficult to repair when the myocardium is damaged by myocardial infarction, myocarditis, aging, or the like. However, it was confirmed by Beltrami et al. That some cardiomyocytes also acquire regenerative ability after infarction (Non-patent Document 1). Furthermore, Laugwitz et al. Revealed the presence of myocardial progenitor cells in the heart of an individual after birth (Non-patent Document 2). However, in view of the decrease in cardiac function after myocardial infarction, it is considered that the normal differentiation and regeneration ability of myocardial progenitor cells present in the adult body is not sufficient to restore cardiac function. Therefore, a compound that proliferates cardiomyocytes has also been reported (Patent Document 1).

In recent years, reagents for differentiating and proliferating myocardial progenitor cells (Patent Document 2) produced by mimicking the developmental stage of cardiomyocytes from pluripotent stem cells such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) Has been reported (Patent Document 3).

Apratoxin A is a 25-membered ring depsipeptide isolated from cyanobacteria and structurally determined by Luesch et al. In 2001 (Non-Patent Document 3) and known to have antitumor activity. There is no known function related to differentiation and proliferation control.

WO2007 / 048352 WO2009 / 118928 WO2012 / 067266

The present invention is to provide a compound for efficiently differentiating and proliferating cardiomyocytes and / or myocardial progenitor cells.

The present inventors screened a drug that promotes the differentiation and proliferation of cardiomyocytes and / or myocardial progenitor cells induced to differentiate from mouse ES cells, and it is clear that the differentiation and proliferation of the cells are promoted by a plurality of cyclic depsipeptides. became. The present invention has been completed based on such findings.

That is, the present invention has the following features.
[1] The following formula (I) or formula (II) (wherein R ₁ and R ₃ are each H or C1-C6 alkyl group, R ₂ is H, C1-C6 alkyl group, trimethylsilyl group and triethyl) R ₄ is a substituent selected from the group consisting of silyl groups, R ₄ is a substituent selected from the group consisting of H, OH, C1-C6 alkoxy groups, F, Cl, Br and I, and LM is CH = Having a structure selected from the group consisting of C (Me), CH = CH, CH ₂ -CH ₂ and CH ₂ -CH (Me), X is O or S, and n is 1 or 2. Or a pharmaceutically acceptable salt, solvate or prodrug thereof as an active ingredient.

[2] R ₁ is an isopropyl group or a t-butyl group, R ₂ is H, R ₃ is a methyl group, R ₄ is a methoxy group, LM is CH = C (Me), The pharmaceutical composition according to [1], wherein X is O or S, and n is 1.
[3] The pharmaceutical composition according to [1], wherein the cyclic depsipeptide is selected from the group consisting of compounds represented by the following formulas (III) to (VIII):

[4] The pharmaceutical composition according to any one of [1] to [3], which is used for the treatment of a heart disease selected from heart failure, ischemic heart disease or cardiomyopathy.
[5] The following formula (I) or formula (II) (wherein R ₁ and R ₃ are each H or C1-C6 alkyl group, R ₂ is H, C1-C6 alkyl group, trimethylsilyl group and triethyl R ₄ is a substituent selected from the group consisting of silyl groups, R ₄ is a substituent selected from the group consisting of H, OH, C1-C6 alkoxy groups, F, Cl, Br and I, and LM is CH = Having a structure selected from the group consisting of C (Me), CH = CH, CH ₂ -CH ₂ and CH ₂ -CH (Me), X is O or S, and n is 1 or 2. A method for producing cardiomyocytes, comprising a step of adding a cyclic depsipeptide represented by (A) to a cardiac progenitor cell.

[6] R ₁ is an isopropyl group or a t-butyl group, R ₂ is H, R ₃ is a methyl group, R ₄ is a methoxy group, LM is CH = C (Me), The method according to [5], wherein X is O or S, and n is 1.
[7] The method according to [5], wherein the cyclic depsipeptide is selected from the group consisting of compounds represented by the following formulas (III) to (VIII):

[8] Any of [5] to [7], wherein the myocardial progenitor cells are in vivo myocardial progenitor cells including side population cells (SP cells), or myocardial progenitor cells derived from pluripotent stem cells. The method described in 1.
[9] The method according to [8], wherein the myocardial progenitor cells derived from the pluripotent stem cells are Flk1 (KDR) positive cells.

When the compound represented by the above formula (I) or formula (II) is brought into contact with the myocardial progenitor cell, the induction efficiency of the myocardial cell can be remarkably improved. It is particularly useful for the differentiation and proliferation of cells, and is contained in a pharmaceutical composition used for the treatment of heart diseases such as myocardial infarction. Alternatively, it is particularly useful for efficiently obtaining cardiomyocytes by contacting cardiomyocyte progenitor cells with the compound.

The differentiation induction rate from myocardial progenitor cells (Flk1-positive cells) to cardiomyocytes (αMHC-positive cells) by 21-2 and APT-1 at each concentration is shown. In the figure, the control is a negative control in the non-addition group, and cyclosporin A is a positive control. The differentiation induction rate from myocardial progenitor cells (Flk1-positive cells) to cardiomyocytes (αMHC-positive cells) by each concentration of APT-7, APT-8, APT-9 and APT-10 is shown. In the figure, the control is a negative control in the non-addition group, and cyclosporin A is a positive control. A shows a protocol for induction from side-population (SP) cells into cardiomyocytes. B shows immunostained images (photographs) of Day 21 cardiomyocytes supplemented with 21-2 using DAPI and anti-cardiac troponin antibody.

The present invention provides a pharmaceutical composition comprising the cyclic depsipeptide represented by the above formula (I) or formula (II) or a salt thereof as an active ingredient. Furthermore, since the cyclic depsipeptide can be efficiently obtained by contacting with the myocardial progenitor cell, a method for producing a cardiomyocyte including the step of contacting the compound with the myocardial progenitor cell is provided.

In the present invention, a depsipeptide is a peptide having one or more ester bonds, and a cyclic depsipeptide is a depsipeptide having at least one ring structure.

A preferred cyclic depsipeptide in the present invention is a compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Wherein R ₁ and R ₃ are each H (hydrogen atom) or a C1-C6 alkyl group,
R ₂ is a substituent selected from the group consisting of H, C1-C6 alkyl group, a trimethylsilyl (TMS) group and triethylsilyl (TES) group, R ₄ is H, OH, C1-C6 alkoxy group, F, A substituent selected from the group consisting of Cl, Br and I, and LM is selected from the group consisting of C (Me) = CH, CH = CH, CH ₂ -CH ₂ and CH (Me) -CH ₂ X is O (oxygen atom) or S (sulfur atom), and n is 1 or 2. )

In the present invention, the “C1-C6 alkyl group” means a linear, branched or cyclic alkyl group, for example, methyl group, ethyl group, n-propyl group, isopropyl group, cyclopropyl group, n -Butyl group, isobutyl group, sec-butyl group, tert-butyl group, cyclobutyl group, n-pentyl group, isopentyl group, neopentyl group, tert-pentyl group, cyclopeentyl group, n-hexyl group, 2,2-dimethylbutyl Groups, 3,3-dimethylbutyl group, 2-ethylbutyl group, and cyclohexyl group.
In the present invention, “C1-C6 alkoxy group” means a linear, branched or cyclic alkoxy group, for example, a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, a cyclopropyloxy group. 1-ethylpropoxy group, 2,2-dimethylpropoxy group, n-butoxy group, isobutyloxy group, tert-butoxy group, n-pentyloxy group, cyclopeentyloxy group, n-hexyloxy group, and cyclohexyl An oxy group etc. are mentioned.

Preferably, the cyclic depsipeptide is a compound described in Formula (III) to Formula (VIII) having a substituent described in Table 1.

In the present invention, the cyclic depsipeptide includes an optical isomer or a racemate. In the present invention, pharmaceutically acceptable salts of cyclic depsipeptides include, for example, inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulfate, nitrate, formate, acetate, propionate. , Maleate, fumarate, succinate, lactate, malate, tartrate, citrate, ascorbate, malonate, oxalate, glycolate, phthalate, benzenesulfonic acid Salts with organic acids such as salts, or alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts, magnesium salts and barium salts; aluminum salts; ammonium salts; trimethylamine, triethylamine, pyridine, Picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, N, N-diethylamine, cyclohexylamine N, N'-dicyclohexylamine, N, N'-dibenzylethylenediamine, N, N-dimethylaminopyridine (DMAP), 1,4-diazabicyclo [2.2.2] octane (DABCO), 1,5-diazabicyclo [ 4.3.0] Salts with organic bases such as nonene-5 (DBN) and 1,8-diazabicyclo [5.4.0] unde-7-cene (DBU); salts with basic amino acids such as arginine, lysine and ornithine Or salts with acidic amino acids such as aspartic acid and glutamic acid. These salts can also be used in combination.

A cyclic depsipeptide prodrug is a compound that is hydrolyzed in vivo to be converted into a cyclic depsipeptide. For example, a derivative in which an amino group is substituted with an alkanoyl group (acyl group) (that is, an amidated derivative), hemiami Examples thereof include nal ether derivatives, derivatives substituted with alkoxycarbonyloxymethyl groups, and N-oxide derivatives.

In the present invention, the cyclic depsipeptide is Doi T, et al. Chem. Asian J.6, 180, 2011, Doi T, et al. Org. Lett., 8, 531, 2006, Numajiri Y, et al. Chem Asian J, 4, 111, 2009, Zou B, et al. Org Lett, 5, 3503, 2003 and Qi-Yin Chen, et al. ACS Med. Chem. Lett., 2, 861-865, 2011 And can be synthesized by a method analogous thereto. Alternatively, as described in Hendrik 凍結 L, et al. J. Am. Chem. Soc. 123, 5418, and 2001, cyanobacteria can be lyophilized and extracted from a dissolved layer in an organic solvent.

The present invention also provides a pharmaceutical composition containing a cyclic depsipeptide. The target disease in the present invention is a heart disease, and examples thereof include heart failure, ischemic heart disease or cardiomyopathy.

The cyclic depsipeptide of the present invention may be administered as it is alone or mixed with a pharmacologically acceptable carrier, excipient, diluent, etc., and administered orally or parenterally as a pharmaceutical composition of an appropriate dosage form. Can do.

Compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like. On the other hand, as a composition for parenteral administration, for example, injections, suppositories and the like are used, and injections include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, infusions, and the like. Dosage forms may be included. These formulations include excipients (eg sugar derivatives such as lactose, sucrose, sucrose, mannitol, sorbitol; starch derivatives such as corn starch, potato starch, alpha starch, dextrin; cellulose derivatives such as crystalline cellulose; Gum arabic; dextran; organic excipients such as pullulan; and silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate and magnesium metasilicate aluminate; phosphates such as calcium hydrogen phosphate; Carbonates such as calcium; inorganic excipients such as sulfates such as calcium sulfate), lubricants (eg, stearic acid metal salts such as stearic acid, calcium stearate, magnesium stearate; talc; Colloidal silica; wax like beeswax and gay wax Borax; adipic acid; sulfate such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL leucine; lauryl sulfate such as sodium lauryl sulfate and magnesium lauryl sulfate; anhydrous silicic acid, silicic acid hydrate Such as silicic acids; and the above-mentioned starch derivatives), binders (for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, and compounds similar to the excipients), disintegrants ( For example, cellulose derivatives such as low substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, internally crosslinked sodium carboxymethyl cellulose; carboxymethyl starch, carboxymethyl starch sodium, crosslinked poly Chemically modified starches and celluloses such as livinylpyrrolidone), emulsifiers (for example, colloidal clays such as bentonite and bee gum; metal hydroxides such as magnesium hydroxide and aluminum hydroxide; sodium lauryl sulfate Anionic surfactants such as calcium stearate; cationic surfactants such as benzalkonium chloride; and nonionic interfaces such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, sucrose fatty acid esters Activators), stabilizers (paraoxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenol, cresol Such phenols; thimerosal; dehydroacetic acid; and sorbic acid), flavoring agents (for example, commonly used sweeteners, acidulants, fragrances, etc.), well-known additives using diluents, etc. It is manufactured by the method.

The dose of the cyclic depsipeptide in the present invention can vary depending on various conditions such as patient symptoms, age, weight and the like.

The dose varies depending on symptoms, age, etc. In the case of oral administration, the lower limit is 0.1 mg (preferably 0.5 mg) and the upper limit is 1000 mg (preferably 500 mg). Can be administered to an adult 1 to 6 times per day at a lower limit of 0.01 mg (preferably 0.05 mg) and an upper limit of 100 mg (preferably 50 mg). The dose may be increased or decreased depending on the symptoms.

The present invention also provides a method for producing cardiomyocytes, comprising the step of adding a cyclic depsipeptide to myocardial progenitor cells. This step may be in vitro or in vivo, but is preferably an in vitro method in which a cyclic depsipeptide is added to isolated myocardial progenitor cells.
Here, the myocardial cell means a myocardial cell having the characteristics of self-pulsation.
The myocardial progenitor cell is a progenitor cell of the cardiomyocyte and has the ability to generate a cardiomyocyte by culture or maturation. For example, a myocardial stem cell and a myocardial progenitor cell contained in a living heart Cells derived from sex stem cells, bone marrow cells, skeletal myoblasts, cells included in adipose-derived mesenchymal cells, or cells differentiated from these cells (JP 2006-115771, JP 2003-325169 and JP-A-2008-307205). Further, myocardial stem cells and myocardial progenitor cells are not particularly distinguished unless otherwise specified. Here, as a myocardial progenitor cell contained in a living heart, cells (SP cells) existing in a side population among cells contained in the heart are exemplified (Oyama T, et al. J Cell Biol. 176, 329- 341, 2007). The SP cell means a cell having a high excretion ability with respect to a DNA fluorescent dye called Hoechst33342. Cardiomyocytes and myocardial progenitor cells may be mixed with each other or isolated.

In the present invention, cardiomyocytes are also characterized by being positive for myocardial markers cardiac troponin (cTNT or troponin T type 2) and / or αMHC (α myosin heavy chain).
In addition, myocardial progenitor cells are not particularly limited, but by being positive for Flk1 / KDR, islet1, Wt1 and / or N-Cadherin and / or present in the side population (SP cell fraction) in FACS analysis Characterized.

In the present invention, cardiac progenitor cells may be prepared by differentiating pluripotent stem cells in vitro. Here, the pluripotent stem cell is a stem cell having pluripotency that can be differentiated into all cells existing in a living body and also having proliferative ability, and is not particularly limited, for example, Embryonic stem (ES) cells, embryonic stem (ntES) cells derived from cloned embryos obtained by nuclear transfer, sperm stem cells (“GS cells”), embryonic germ cells (“EG cells”), induced pluripotent stems (iPS) cells, cultured fibroblasts, pluripotent cells derived from bone marrow stem cells (Muse cells) and the like are included.

(A) Embryonic stem cells ES cells are stem cells established from the inner cell mass of early embryos (for example, blastocysts) of mammals such as humans and mice, and having pluripotency and proliferation ability by self-replication.

ES cells are embryonic stem cells derived from the inner cell mass of the blastocyst, the embryo after the morula, in the 8-cell stage of a fertilized egg, and have the ability to differentiate into any cell that constitutes an adult, so-called differentiation. And ability to proliferate by self-replication. ES cells were discovered in mice in 1981 (MJ Evans and MH Kaufman (1981), Nature 292: 154-156), and then ES cell lines were established in primates such as humans and monkeys (JA Thomson et al. (1998), Science 282: 1145-1147; JA Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92: 7844-7848; JA Thomsonet al. (1996), Biol. Reprod. 55: 254-259; JA Thomson and VS Marshall (1998), Curr. Top. Dev. Biol., 38: 133-165).

ES cells can be established by taking an inner cell mass from a blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder. In addition, maintenance of cells by subculture is performed using a culture solution to which substances such as leukemia inhibitory factor (LIF) and basic fibroblast growth factor (basic fibroblast growth factor (bFGF)) are added. It can be carried out. For methods of establishing and maintaining human and monkey ES cells, see, for example, USP 5,843,780; Thomson JA, et al. (1995), Proc Natl. Acad. Sci. U S A. 92: 7844-7848; Thomson JA, et al. (1998), Science. 282: 1145-1147; H. Suemori et al. (2006), Biochem. Biophys. Res. Commun., 345: 926-932; M. Ueno et al. (2006), Proc. Natl. Acad. Sci. USA, 103: 9554-9559; H. Suemori et al. (2001), Dev. Dyn., 222: 273-279; H. Kawasaki et al. (2002), Proc. Natl Acad. Sci. USA, ； 99: 1580-1585; Klimanskaya I, et al. (2006), Nature. 444: 481-485.

For example, DMEM / F-12 culture medium supplemented with 0.1 mM 2-mercaptoethanol, 0.1 mM non-essential amino acid, 2 mM L-glutamic acid, 20% KSR and 4 ng / ml bFGF is used as the culture medium for ES cell production. Human ES cells can be maintained in a humid atmosphere of 37 ° C., 2% CO ₂ /98% air (O. Fumitaka et al. (2008), Nat. Biotechnol., 26: 215-224). ES cells also need to be passaged every 3-4 days, where passage is eg 0.25% trypsin and 0.1 mg / ml collagenase IV in PBS containing 1 mM CaCl ₂ and 20% KSR. Can be used.

ES cells can be generally selected by Real-Time PCR using the expression of gene markers such as alkaline phosphatase, Oct-3 / 4, Nanog as an index. In particular, in the selection of human ES cells, the expression of gene markers such as OCT-3 / 4, NANOG, and ECAD can be used as an index (E. Kroon et al. (2008), Nat. Biotechnol., 26: 443). -452).

Human ES cell lines, for example, WA01 (H1) and WA09 (H9) are obtained from the WiCell Research Institute, and KhES-1, KhES-2 and KhES-3 are obtained from the Institute of Regenerative Medicine (Kyoto, Japan), Kyoto University Is possible.

(B) Sperm stem cells Sperm stem cells are testis-derived pluripotent stem cells that are the origin of spermatogenesis. Like ES cells, these cells can be induced to differentiate into various types of cells, and have characteristics such as the ability to create chimeric mice when transplanted into mouse blastocysts (M. Kanatsu-Shinohara et al. ( 2003) Biol. Reprod., 69: 612-616; K. Shinohara et al. (2004), Cell, 119: 1001-1012). It is capable of self-replication in a culture medium containing glial cell line-derived neurotrophic factor (GDNF), and by repeating subculture under the same culture conditions as ES cells, Stem cells can be obtained (Masatake Takebayashi et al. (2008), Experimental Medicine, Vol. 26, No. 5 (extra number), 41-46, Yodosha (Tokyo, Japan)).

(C) Embryonic germ cells Embryonic germ cells are cells that are established from embryonic primordial germ cells and have the same pluripotency as ES cells, such as LIF, bFGF, stem cell factor, etc. It can be established by culturing primordial germ cells in the presence of these substances (Y. Matsui et al. (1992), Cell, 70: 841-847; JL Resnick et al. (1992), Nature, 359: 550 -551).

(D) Artificial pluripotent stem cells Artificial pluripotent stem (iPS) cells can be produced by introducing specific reprogramming factors into somatic cells in the form of DNA or protein, which is almost equivalent to ES cells It is an artificial stem cell derived from a somatic cell having the characteristics of, for example, differentiation pluripotency and proliferation ability by self-replication (K. Takahashi and S. Yamanaka (2006) Cell, 126: 663-676; K. Takahashi et al (2007), Cell, 131: 861-872; J. Yu et al. (2007), Science, 318: 1917-1920; Nakagawa, M. et al., Nat. Biotechnol. 26: 101-106 (2008); International publication WO 2007/069666). The reprogramming factor is a gene specifically expressed in ES cells, its gene product or non-cording RNA, a gene that plays an important role in maintaining undifferentiation of ES cells, its gene product or non-coding RNA, or It may be constituted by a low molecular compound. Examples of genes included in the reprogramming factor include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15 -2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1 etc. are exemplified, and these reprogramming factors may be used alone or in combination. As combinations of reprogramming factors, WO2007 / 069666, WO2008 / 118820, WO2009 / 007852, WO2009 / 032194, WO2009 / 058413, WO2009 / 057831, WO2009 / 075119, WO2009 / 079007, WO2009 / 091659, WO2009 / 101084, WO2009 / 101407, WO2009 / 102983, WO2009 / 114949, WO2009 / 117439, WO2009 / 126250, WO2009 / 126251, WO2009 / 126655, WO2009 / 157593, WO2010 / 009015, WO2010 / 033906, WO2010 / 033920, WO2010 / 042800, WO2010 / 050626, WO 2010/056831, WO2010 / 068955, WO2010 / 098419, WO2010 / 102267, WO 2010/111409, WO 2010/111422, WO2010 / 115050, WO2010 / 124290, WO2010 / 147395, WO2010 / 147612, Huangfu D, et al. 2008), Nat. Biotechnol., 26: 795-797, Shi Y, et al. (2008), Cell Stem Cell, 2: 525-528, Eminli S, et al. (2008), Stem Cells. 26: 2467 -2474, Huangfu D, et al. (2008), Nat Biotechnol. 26: 1269-1275, Shi Y, et al. (2008), Cell Stem Cell, 3, 568-574, Zhao Y, et al. (2008 ), Cell Stem Cell, 3: 475-479, Marson A, (2008), Cell Stem Cell, 3, 132-135, Feng B, et al. (2009), Nat Cell Biol. 11: 197-203, RL Judson et al., (2009), Nat. Biotech., 27: 459-461, Lyssiotis CA, et al. (2009), Proc Natl Acad Sci US A. 106: 8912-8917, Kim JB, et al. 2009), Nature. 461: 649-643, Ichida JK, et al. (2009), Cell Stem Cell. 5: 491-503, Heng JC, et al. (2010), Cell Stem Cell. 6: 167-74 , Han J, et al. (2010), Nature. 463: 1096-100, MaliP, et al. (2010), Stem Cells. 28: 713-720, Maekawa M, et al. (2011), Nature. : The combination described in 225-9.

The reprogramming factors include histone deacetylase (HDAC) inhibitors [for example, small molecule inhibitors such as valproate (VPA), trichostatin A, sodium butyrate, MC 1293, M344, siRNA and shRNA against HDAC (eg , Nucleic acid expression inhibitors such as HDAC1 siRNA Smartpool ((Millipore), HuSH 29mer shRNA Constructs against HDAC1 (OriGene), etc.)], MEK inhibitors (eg PD184352, PD98059, U0126, SL327 and PD0325901), Glycogen synthase kin -3 inhibitors (eg, Bio and CHIR99021), DNA methyltransferase inhibitors (eg, 5-azacytidine), histone methyltransferase inhibitors (eg, small molecule inhibitors such as BIX-01294, Suv39hl, Suv39h2, SetDBl and G9a Nucleic acid expression inhibitors such as siRNA and shRNA), L-channelLcalcium agonist (eg Bayk8644), butyric acid, TGFβ inhibitor or ALK5 inhibitor (eg LY364947, SB4315) 42, 616453 and A-83-01), p53 inhibitors (eg siRNA and shRNA against p53), ARID3A inhibitors (eg siRNA and shRNA against ARID3A), miR-291-3p, miR-294, miR-295 and miRNA such as mir-302, Wnt Signaling (eg soluble Wnt3a), neuropeptide Y, prostaglandins (eg prostaglandin E2 and prostaglandin J2), hTERT, SV40LT, UTF1, IRX6, GLISL, PITX2, DMRTBl Factors used for the purpose of improving establishment efficiency such as the above are also included. In this specification, factors used for the purpose of improving establishment efficiency are not distinguished from initialization factors. And

In the case of a protein form, the reprogramming factor may be introduced into a somatic cell by a technique such as lipofection, fusion with a cell membrane-permeable peptide (for example, HIV-derived TAT and polyarginine), or microinjection.

On the other hand, in the case of DNA, it can be introduced into somatic cells by techniques such as vectors such as viruses, plasmids, artificial chromosomes, lipofection, liposomes, and microinjection. Virus vectors include retrovirus vectors, lentivirus vectors (cell, 126, pp.663-676, 2006; Cell, 131, pp.861-872, 2007; Science, 318, pp.1917-1920, 2007 ), Adenovirus vectors (Science, 322, 945-949, 2008), adeno-associated virus vectors, Sendai virus vectors (WO 2010/008054) and the like. Examples of artificial chromosome vectors include human artificial chromosomes (HAC), yeast artificial chromosomes (YAC), and bacterial artificial chromosomes (BAC, PAC). As a plasmid, a plasmid for mammalian cells can be used (Science, 322: 949-953, 2008). The vector can contain regulatory sequences such as a promoter, enhancer, ribosome binding sequence, terminator, polyadenylation site, etc. so that a nuclear reprogramming substance can be expressed. Selective marker sequences such as kanamycin resistance gene, ampicillin resistance gene, puromycin resistance gene, thymidine kinase gene, diphtheria toxin gene, reporter gene sequences such as green fluorescent protein (GFP), β-glucuronidase (GUS), FLAG, etc. Can be included. In addition, the above vector has a LoxP sequence before and after the introduction of the gene into a somatic cell in order to excise the gene or promoter encoding the reprogramming factor and the gene encoding the reprogramming factor that binds to it. May be.

In the case of RNA, it may be introduced into somatic cells by techniques such as lipofection and microinjection, and in order to suppress degradation, RNA incorporating 5-methylcytidine and pseudouridine® (TriLink® Biotechnologies) is used. Yes (Warren L, (2010) Cell Stem Cell. 7: 618-630).

Examples of the culture medium for inducing iPS cells include DMEM, DMEM / F12 or DME culture medium containing 10 to 15% FBS (these culture media include LIF, penicillin / streptomycin, puromycin, L-glutamine). , Non-essential amino acids, β-mercaptoethanol, etc.) or commercially available culture media (eg, culture media for mouse ES cell culture (TX-WES culture solution, Thrombo X), primate ES cells) Culture medium for culture (primate ES / iPS cell culture medium, Reprocell), serum-free medium (mTeSR, Stemcell Technology).

As an example of the culture method, for example, a somatic cell is brought into contact with a reprogramming factor on a DMEM or DMEM / F12 medium containing 10% FBS at 37 ° C. in the presence of 5% CO ₂ for about 4 to 7 days. Then, re-spread the cells on feeder cells (for example, mitomycin C-treated STO cells, SNL cells, etc.), and use bFGF-containing primate ES cell culture medium about 10 days after contact between the somatic cells and the reprogramming factor. Culturing and generating iPS-like colonies about 30 to about 45 days or more after the contact.

Alternatively, 10% FBS-containing DMEM medium (including LIF, penicillin / streptomycin, etc.) on feeder cells (eg, mitomycin C-treated STO cells, SNL cells, etc.) in the presence of 5% CO ₂ at 37 ° C. Can be suitably included with puromycin, L-glutamine, non-essential amino acids, β-mercaptoethanol, etc.) and can form ES-like colonies after about 25 to about 30 days or more . Desirably, instead of feeder cells, somatic cells to be reprogrammed themselves are used (Takahashi K, et al. (2009), PLoS One. 4: e8067 or WO2010 / 137746), or extracellular matrix (eg, Laminin- 5 (WO2009 / 123349) and Matrigel (BD)) are exemplified.

In addition to this, a method of culturing using a medium not containing serum is also exemplified (Sun N, et al. (2009), Proc Natl Acad Sci U S A. 106: 15720-15725). Furthermore, in order to increase the establishment efficiency, iPS cells may be established under hypoxic conditions (oxygen concentration of 0.1% or more and 15% or less) (Yoshida Y, et al. (2009), Cell Stem Cell. 5: 237 -241 or WO2010 / 013845).

During the culture, the culture medium is exchanged with a fresh culture medium once a day from the second day onward. The number of somatic cells used for nuclear reprogramming is not limited, but ranges from about 5 × 10 ³ to about 5 × 10 ⁶ cells per 100 cm ^{2 of} culture dish.

IPS cells can be selected according to the shape of the formed colonies. On the other hand, when a drug resistance gene that is expressed in conjunction with a gene that is expressed when somatic cells are initialized (for example, Oct3 / 4, Nanog) is introduced as a marker gene, a culture solution containing the corresponding drug (selection The established iPS cells can be selected by culturing with the culture medium. In addition, if the marker gene is a fluorescent protein gene, iPS cells are selected by observing with a fluorescence microscope, in the case of a luminescent enzyme gene, by adding a luminescent substrate, and in the case of a chromogenic enzyme gene, by adding a chromogenic substrate can do.

As used herein, the term “somatic cell” refers to any animal cell (preferably, a mammalian cell including a human) except a germ line cell such as an egg, oocyte, ES cell, or totipotent cell. Say. Somatic cells include, but are not limited to, fetal (pup) somatic cells, neonatal (pup) somatic cells, and mature healthy or diseased somatic cells. , Passage cells, and established cell lines. Specifically, somatic cells include, for example, (1) neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue stem cells such as dental pulp stem cells (somatic stem cells), (2) tissue progenitor cells, (3) lymphocytes, epithelium Cells, endothelial cells, muscle cells, fibroblasts (skin cells, etc.), hair cells, hepatocytes, gastric mucosal cells, enterocytes, spleen cells, pancreatic cells (exocrine pancreas cells, etc.), brain cells, lung cells, kidney cells Examples thereof include differentiated cells such as fat cells.

In addition, when iPS cells are used as a material for transplantation cells, it is desirable to use somatic cells having the same or substantially the same HLA genotype as the transplant destination individual from the viewpoint that rejection does not occur. Here, “substantially the same” means that the HLA genotype matches the transplanted cells to such an extent that an immune response can be suppressed by an immunosuppressive agent. For example, HLA-A, HLA-B And somatic cells having an HLA type in which 3 loci of HLA-DR or 4 loci plus HLA-C are matched.

(E) Cloned embryo-derived ES cells obtained by nuclear transfer nt ES cells are cloned embryo-derived ES cells produced by nuclear transfer technology and have almost the same characteristics as ES cells derived from fertilized eggs (T. Wakayama et al. (2001), Science, 292: 740-743; S. Wakayama et al. (2005), Biol. Reprod., 72: 932-936; J. Byrne et al. (2007) , Nature, 450: 497-502). That is, an ES cell established from an inner cell mass of a clonal embryo-derived blastocyst obtained by replacing the nucleus of an unfertilized egg with the nucleus of a somatic cell is an nt ES (nuclear transfer ES) cell. For the production of nt ES cells, a combination of nuclear transfer technology (JB Cibelli et al. (1998), Nature Biotechnol., 16: 642-646) and ES cell production technology (above) is used (Wakayama). Seika et al. (2008), Experimental Medicine, Vol. 26, No. 5 (extra number), 47-52). Nuclear transfer can be initialized by injecting a somatic cell nucleus into a mammal's enucleated unfertilized egg and culturing for several hours.

(F) Multilineage-differentiating Stress Enduring cells (Muse cells)
Muse cells are pluripotent stem cells produced by the method described in WO2011 / 007900. Specifically, fibroblasts or bone marrow stromal cells are treated with trypsin for a long time, preferably 8 or 16 hours. It is a pluripotent cell obtained by suspension culture after treatment, and is positive for SSEA-3 and CD105.

In the present invention, the method for inducing differentiation from pluripotent stem cells to myocardial progenitor cells is not particularly limited. For example, the following method can be used.

Pluripotent stem cells may be separated by any method, and adhesion culture or / and co-culture with feeder cells may be performed using a culture dish subjected to suspension culture or coating treatment. Further, suspension culture and adhesion culture may be performed in combination. Here, as a separation method, a separation solution having mechanical, protease activity and collagenase activity (for example, Accutase (TM) and Accumax (TM)) or a separation solution having only collagenase activity may be used. . Here, in suspension culture, the surface of the culture dish is not artificially treated (for example, coated with an extracellular matrix or the like) for the purpose of improving adhesion to cells, or artificially adhered. Can be used (for example, coating treatment with polyhydroxyethyl methacrylic acid (poly-HEMA)). In the adhesion culture, for example, a culture dish coated with matrigel (BD), type I collagen, type IV collagen, gelatin, laminin, heparan sulfate proteoglycan, or entactin, and combinations thereof can be used. The cells used for co-culture are OP9 cells (Nishikawa, SI et al, Development 125, 1747-1757 (1998)) or END-2 cells (Mummery C, et al, Circulation. 107: 2733-40 (2003 )) Is exemplified.

The medium in this step can be prepared using a medium used for animal cell culture as a basal medium. Examples of the basal medium include IMDM medium, Medium 、 199 medium, Eagle's'Minimum Essential Medium (EMEM) medium, αMEM medium, Doulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium Etc. are included. ΑMEM or DMEM is preferable. The medium may contain serum or may be serum-free. If necessary, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum substitute for FBS during ES cell culture), fatty acid, insulin, collagen precursor, trace element, 2-mercaptoethanol, 3'-thiol May contain one or more serum replacements such as glycerol, ITS-supplements, B27-supplements, N2-supplements, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, cytokines, Wnt It may also contain one or more substances such as signal inhibitors, antibiotics, antioxidants, pyruvate, buffers, inorganic salts. Examples of cytokines include activin A and BMP4. As Wnt signal inhibitors, XAV939 (Shih-Min A. Huang, et al, Nature 461, 614-620, 2009), vitamin A (retinoic acid), lithium, flavonoid, Dickkopf1 (Dkk1), insulin-like growth factor binding protein Examples include (IGFBP) (WO2009 / 131166), siRNA for β-catenin, and the like.

The culture temperature is not limited to the following, but is about 30 to 40 ° C., preferably about 37 ° C. The culture is performed in an atmosphere of CO ₂ -containing air, and the CO ₂ concentration is preferably about 2 to 5%. is there. The culture time is the number of days required for Flk1 / KDR to be expressed, for example, 4 days or longer.

In the present invention, the step of adding a cyclic depsipeptide for producing cardiomyocytes to myocardial progenitor cells can be performed under the same conditions as in the differentiation induction method from pluripotent stem cells to myocardial progenitor cells. The period during which the cyclic depsipeptide is added is the number of days required for cTNT or αMHC to be expressed, for example, 6 days or longer. The concentration at which cyclic depsipeptide is added is appropriately selected according to the type of progenitor cells and cyclic depsipeptide to be used, but is preferably 0.25 nM to 25 nM.

[Example]
Hereinafter, the present invention will be described more specifically with reference to examples, but it goes without saying that the present invention is not limited thereto.

By inducing differentiation from an EMG7 mouse ES cell having an EGFP gene driven by a mouse α-myosin heavy chain (MHC) promoter and using purified Flk1-positive cells as myocardial progenitor cells, adding cyclic depsipeptide and culturing, Differentiation into cardiomyocytes was induced (Yamashita, JK et al, FASEB J. 19, 1534-1536 (2005)). At the same time as seeding these Flk1-positive cells onto OP9 stromal cells, cyclosporin A, 21-2 (formula (III)) (Luesch, Bioorg Med Chem, 2002) and APT-1 (formula (IV)) (Luesch, J Am Chem Soc, 2001) was added. Similarly, as a control, culturing without addition of a drug was performed. After seeding on OP9 cells, the cells were collected 6 days later, and the number of EGFP positive cells was counted by FACS. Here, the number of EGFP positive cells relative to the total number of collected cells was calculated, and each drug was evaluated using the ratio (Fold increase) of this value with respect to the control group without addition. The results are shown in FIG. 21-2 was able to confirm remarkable activity in the concentration range of 2 nM to 4 nM. In addition, APT-1 was confirmed to have significant activity in the concentration range of 3 nM to 4.5 nM. These activities were higher than cyclosporin A.

Using the same method as in Example 1, APT-7 (formula (V)), APT-8 (formula (VI)) (Numajiri Y, et al, Chem. Asian J. 2009, 4, 111-125) , APT-9 (formula (VII)) (Numajiri Y, et al, Chem. Asian J. 2009, 4, 111-125) and APT-10 (formula (VIII)) (Doi T, et al, Chem. Asian J. 2011, 6, 180-188) was also evaluated. The results are shown in FIG. APT-7, APT-8, APT-9 and APT-10 were able to confirm remarkable activity in the concentration ranges of 10 nM, 7.5 nM, 7.5 nM to 20 nM and 1 nM to 1.5 nM, respectively. These activities were higher than cyclosporin A.

Side population cells (SP cells) in cardiomyocytes were isolated using the method of Oyama et al. (Oyama T, et al. J Cell Biol. 176, 329-341, 2007). Specifically, cardiomyocytes extracted from newborn rats were suspended at 1.0 × 10 ⁶ cells / ml in PBS containing 3% FBS, 1 μg / ml Hoechst 33342 was added, and incubated at 37 ° C. for 60 minutes in the dark. Thereafter, the cells were isolated as SP cells using a flow cytometer. SP cells were excited as Hoechst 33342 with a 350 nm UV laser and separated as cells detected at specific locations at 450 nm (Hoechst blue) and 675 nm (Hoechst red) (Goodell MA, et al. J Exp Med. 183 : 1797-1806, 1996). At this time, cells stained with Propidium iodide were removed as dead cells. The obtained SP cells were cultured in IMDM containing 10% FBS, and after 21 hours, 21-2 was added and cultivation was continued for 72 hours. Furthermore, the culture was continued under the condition of no addition of 21-2, and the cells were observed by cTNT antibody staining 3 weeks after SP cell isolation (FIG. 3A). The result is shown in FIG. 3B. It was confirmed that cardiomyocytes with sarcomere structure were induced and partly pulsated. Based on the above, it is presumed that 21-2 has at least the same function as oxytocin and trichostatin A, which have been reported so far, capable of inducing differentiation from myocardial SP cells to cardiomyocytes.

From the above results, it was confirmed that the cyclic depsipeptide shown here has the ability to induce cardiomyocyte differentiation from myocardial progenitor cells.

While the invention has been described with emphasis on preferred embodiments, it will be apparent to those skilled in the art that the preferred embodiments can be modified. The present invention contemplates that the present invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the appended claims.
The contents of all publications, including the patents and patent application specifications mentioned herein, are hereby incorporated by reference herein to the same extent as if all were expressly cited. .

According to the present invention, the efficiency of inducing cardiomyocytes from myocardial progenitor cells can be remarkably improved, which is particularly useful for the treatment of heart diseases or cell transplantation using pluripotent stem cells.

Claims

The following formula (I) or formula (II) (wherein R 1 and R 3 are each H or C1-C6 alkyl group, R 2 is H, C1-C6 alkyl group, trimethylsilyl group and triethylsilyl group) R 4 is a substituent selected from the group consisting of H, OH, C1-C6 alkoxy group, F, Cl, Br and I, and LM is C (Me) = Having a structure selected from the group consisting of CH, CH═CH, CH 2 —CH 2 and CH (Me) —CH 2 , X is O or S, and n is 1 or 2. A pharmaceutical composition comprising the represented cyclic depsipeptide or a pharmaceutically acceptable salt, solvate or prodrug thereof as an active ingredient.
R 1 is an isopropyl group or a t-butyl group, R 2 is H, R 3 is a methyl group, R 4 is a methoxy group, LM is C (Me) = CH, and X is O Or the pharmaceutical composition of Claim 1 which is S and n is 1.
The pharmaceutical composition according to claim 1, wherein the cyclic depsipeptide is selected from the group consisting of compounds represented by the following formulas (III) to (VIII):
The pharmaceutical composition according to any one of claims 1 to 3, which is used for the treatment of a heart disease selected from heart failure, ischemic heart disease or cardiomyopathy.
The following formula (I) or formula (II) (wherein R 1 and R 3 are each H or C1-C6 alkyl group, R 2 is H, C1-C6 alkyl group, trimethylsilyl group and triethylsilyl group) R 4 is a substituent selected from the group consisting of H, OH, C1-C6 alkoxy group, F, Cl, Br and I, and LM is C (Me) = Having a structure selected from the group consisting of CH, CH═CH, CH 2 —CH 2 and CH (Me) —CH 2 , X is O or S, and n is 1 or 2. A method for producing cardiomyocytes, comprising a step of adding the expressed cyclic depsipeptide to myocardial progenitor cells.
R 1 is an isopropyl group or a t-butyl group, R 2 is H, R 3 is a methyl group, R 4 is a methoxy group, LM is C (Me) = CH, and X is O 6. The method of claim 5, wherein S is n and n is 1.
The method according to claim 5, wherein the cyclic depsipeptide is selected from the group consisting of compounds represented by the following formulas (III) to (VIII).
The myocardial progenitor cell according to any one of claims 5 to 7, wherein the myocardial progenitor cell is an in vivo myocardial progenitor cell including side-population cells (SP cells) or a myocardial progenitor cell derived from a pluripotent stem cell. Method.
The method according to claim 8, wherein the myocardial progenitor cell derived from the pluripotent stem cell is a Flk1 (KDR) positive cell.